Methods for diagnosis using anti-cytokine receptor antibodies

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S130100, C424S133100, C424S138100, C436S057000, C436S064000, C436S164000, C514S001000, C514S002600

Reexamination Certificate

active

07727528

ABSTRACT:
Labeled antibodies, antibody fragments or peptides binding to soluble cytokines or cytokine receptors are used to diagnose whether a patient has cancer or an autoimmune disease. In a preferred embodiment, a radiolabelled tag that is chemically bound to a peptide, antibody, or antibody fragment specific for sTNFR-1 and/or sTNFR2 is injected into a patient with a tumor, or suspected tumor, or with any disease associated with STNF-1/STNF-2. The patient is then imaged using standard nuclear imaging equipment to detect areas or sites of concentration of the radiolabel and/or receptor/inhibitor and/or antigen. By screening for cancer by the substances it produces, using an injected antibody to that substance with a tracer attached to it, one can detect cancer at a very early stage, potentially even microscopically.

REFERENCES:
patent: 2002/0012665 (2002-01-01), Hanna
patent: 2002/0146369 (2002-10-01), Goldenberg
patent: 2003/0054421 (2003-03-01), Rosen et al.
patent: 2003/0138426 (2003-07-01), Ni et al.
patent: 2003/0185832 (2003-10-01), Thorpe et al.
patent: 2005/0089928 (2005-04-01), Short et al.
patent: WO 94/02627 (1994-02-01), None
patent: WO 03/056896 (2003-07-01), None
patent: WO 2005/107802 (2005-11-01), None
Lavabre-Bertrand, Thierry. Detection of membrane and soluble interleukin-6 receptor in lymphoid malignancies British Journal of Haematology 91(4): 871-877, Dec. 1995.
Qui, Yuhua et al. Establishment and application of radioimmunoassay for detecting human soluble IL-6Ralpha. Zhonghua Jianyan Yixue Zazhi 26(7): 424-427, 2003.
Abbate, et al., “Tumor necrosis factor and soluble interleukin-2 receptor: two immunological biomarkers in female neoplasms”,Eur J Gynaecol Oncol, 13(1 Suppl):92-6 (1992).
Adair, “Engineering antibodies for therapy”,Immunol. Rev., 130:5-40 (1992).
Aggarwal, et al., “The role of TNF and its family members in inflammation and cancer: lessons from gene deletion”,Curr Drug Targets Inflamm Allergy, 1(4):327-41 (2002).
Ardizzoia, et al., “Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease”,J Biol Regul Homeost Agents, 6(3):103-7 (1992).
Berkower, “The promise and pitfalls of monoclonal antibody therapeutics”,Curr. Opin. Biotechnology, 7:622-8 (1996).
Bjornberg, et al., “Mechanisms involved in the processing of the p55 and the p75 tumor necrosis factor (TNF) receptors to soluble receptor forms”,Lymphokine Cytokine Res., 13(3):203-11 (1994).
Bouwmeester, et al., “A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway”,Nat Cell Biol, 6(2):97-105 (2004).
Brumley, et al., “Radiolabeled monoclonal antibodies”,AORN J., 62: 343-355 (1995).
Clackson, et al., “Making antibody fragments using phage display libraries”,Nature, 352(6336):624-688 (1991).
Csehi, et al., “Tumor necrosis factor (TNF) interferes with insulin signaling through the p55 TNF receptor death domain”,Biochem Biophys Res Commun, 329(1):397-405 (2005).
Daugherty, et al.,Nucl. Acids Res., “Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins”, 19:2471-2476 (1991).
Eliopoulos, et al., “The role of the CD40 pathway in the pathogenesis and treatment of cancer”Curr Opin Pharmacol, 4(4):360-7 (2004).
Engelmann, et al., “Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors”,J Biol Chem, 265(3):1531-6 (1990).
Feng, “Regulatory roles and molecular signaling of TNF family members in osteoclasts”,Gene, 350(1):1-13 (2005).
Forrest, et al., “Modulation of cytokine release by purine receptors in patients with rheumatoid arthritis,”Clin Exp Rheumatol., 23(1):89-92 (2005).
Fraker, et al., “Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril”,Biochem. Biophys. Res. Commun., 80:849-857 (1978).
Gadducci, et al., “Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in endometrial cancer”,Anticancer Res, 16(5B):3125-8 (1996).
Gadducci, et al., “Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer”,Gynecol Oncol, 58(2):184-8 (1995).
Golovko, et al., “Vitamin D-induced up-regulation of tumour necrosis factor alpha (TNF-alpha) in prostate cancer cells”,Life Sci., 77(5):562-77 (2005).
Grell, et al., “The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor”,Proc Natl Acad Sci U S A., 95(2):570-5 (1998).
Grosen, et al., “Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy”,Gynecol Oncol, 50(1):68-77 (1993).
Hadziselimovic, “Reply: Urinary excretion of TNF receptors”,Gut, 38(1):153-4 (1996), Abstract only.
Hasegawa, et al, “Increased soluble tumor necrosis factor receptor levels in the serum of elderly people”,Gerontology, 46(4):185-8 (2000).
Holtmann, et al., “The emerging distinct role of TNF-receptor 2 (p80) signaling in chronic inflammatory disorders”,Arch Immunol Ther Exp(Warsz), 50(4):279-88 (2002).
Hyer, et al., “Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells”,Cancer Res, 65(11):4799-808 (2005).
Iborra, et al., “Oxidative stress and autoimmune response in the infertile woman”,Chem Immunol Allergy, 88:150-62 (2005).
Ireland, et al., “Interleukin (IL)-12 receptor beta1 or IL-12 receptor beta 2 deficiency in mice indicates that IL-12 and IL-23 are not essential for host recovery from viral encephalitis”,Viral Immunol., 18(2):397-402 (2005).
Jaakkola, “In vivo detection of vascular adhesion protein-1 in experimental inflammation”,Amer.J. Pathol., 157:463-471 (2000).
Jablonska, et al., “Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients”,Eur Cytokine Netw, 9(2):155-9 (1998).
Jacob, et al., “Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human hepatocellular carcinoma cells”,World J Gastroenterol, 11(17):2552-6 (2005).
Jakobovits, “The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice”,Exp. Opin. Invest. Drugs, 7:607-614 (1998).
Kim, et al., “Identification of naturally secreted soluble form of TL1A, a TNF-like cytokine”,J Immunol Methods, 298(1-2):1-8 (2005).
Lentz, “The phylogeny of oncology,”Mol Biotherm., 2:137-144 (1990).
Liu, et al., “Molecular mechanism of TNF signaling and beyond”,Cell Res, 15(1):24-7 (2005).
Macallan, et al., “Development of a novel TNF alpha ligand-receptor binding assay for screening NATCHEM Libraries”,J Recept Signal Transduct Res, 17(1-3):521-9 (1997).
Maier, et al., “Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study”,J Neurotrauma, 22(7):822-35 (2005).
Malmberg, “Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?”Cancer Immunol Immunother, 53(10):879-92 (2004).
Mendez, et al., “Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice”,Nat. Genet., 15:146-156 (1997).
Mercer, et al., “Natural

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods for diagnosis using anti-cytokine receptor antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for diagnosis using anti-cytokine receptor antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosis using anti-cytokine receptor antibodies will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4245894

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.